
|Videos|November 14, 2018
The Evolution of the Ovarian Cancer Treatment Paradigm
Author(s)Maurie Markman, MD
Maurie Markman, MD, president of Medicine and Science, Cancer Treatment Centers of America, discusses how the ovarian cancer treatment paradigm has evolved over the past 30 years.
Advertisement
Maurie Markman, MD, president of Medicine and Science, Cancer Treatment Centers of America, discusses how the ovarian cancer treatment paradigm has evolved over the past 30 years.
Treatment has evolved from acute management over a short period of time to using far more precise and less toxic therapies over many years. The disease still remains fatal in a majority of patients, but the overall survival has transformed from 1 to 2 years to 3 to 6 years.
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Enfortumab Vedotin Plus Pembrolizumab Improves Survival in MIBC
2
FDA Grants Regular Approval to Rucaparib for BRCA-Mutated mCRPC
3
Teclistamab/Daratumumab Earns FDA Priority Voucher for R/R Myeloma
4
Early Relapse Guides Use of CAR T vs Other Options in LBCL
5








































